Journal: European Journal of Endocrinology
Article Title: Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome
doi: 10.1530/EJE-20-0325
Figure Lengend Snippet: Treatment-naïve/prepubertal (NPP) patient characteristics at baseline in responders and poor-responders without LS (enrolled population). Responders were defined as patients with change in height SDS in year 1 of ≥0.3; poor-responders were defined as patients with change in height SDS in year 1 of <0.3.
Article Snippet: Recombinant human IGF1 (rhIGF1; mecasermin, Increlex ® ; Ipsen Pharma, Boulogne-Billancourt, France) therapy stimulates linear growth in children with SPIGFD ( , ) and improves adult height ( ).
Techniques: Injection, Biomarker Discovery